Kostas Biliouris
Stock Analyst at BMO Capital
(0.80)
# 3,635
Out of 4,829 analysts
54
Total ratings
19.57%
Success rate
-24.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $29.48 | +144.23% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $12.45 | +301.61% | 1 | Mar 12, 2025 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $50 | $7.06 | +608.22% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $3.85 | +549.35% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $33.51 | +34.29% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $8.62 | +480.05% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $5.25 | +547.62% | 3 | Jan 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $13.24 | +164.35% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $1.56 | +993.25% | 2 | Aug 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $3.34 | +1,097.60% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $32.24 | +179.16% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $234 | $267.60 | -12.56% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $200 | $36.31 | +450.81% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $16.01 | +649.53% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $18.25 | +212.33% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $35.67 | +3.73% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $61.33 | +63.05% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $1.37 | +1,286.86% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $4.30 | +1,341.86% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $37.45 | +161.68% | 1 | Jun 17, 2022 |
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $29.48
Upside: +144.23%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $12.45
Upside: +301.61%
Rocket Pharmaceuticals
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $7.06
Upside: +608.22%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $3.85
Upside: +549.35%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $33.51
Upside: +34.29%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $8.62
Upside: +480.05%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $5.25
Upside: +547.62%
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $13.24
Upside: +164.35%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.56
Upside: +993.25%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $3.34
Upside: +1,097.60%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $32.24
Upside: +179.16%
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $267.60
Upside: -12.56%
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $36.31
Upside: +450.81%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $16.01
Upside: +649.53%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $18.25
Upside: +212.33%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $35.67
Upside: +3.73%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $61.33
Upside: +63.05%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $1.37
Upside: +1,286.86%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $4.30
Upside: +1,341.86%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $37.45
Upside: +161.68%